On Aug. 18, the U.S. Food and Drug Administration (FDA) approved Addyi (flibanserin) to treat acquired, generalized hypoactive sexual desire disorder in premenopausal women. Read more.
FDA approves drug for sexual desires disorders in women
Share
Get your free access to the exclusive newsletter of American Nurse Journal and gain insights for your nursing practice.
NurseLine Newsletter
*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.
